Gynecologic Cancer,Ovarian Cancer Maintenance Olaparib in PSROC: Safety and Efficacy Regardless of BRCA Status Mar 28, 2023
Gynecologic Cancer,Ovarian Cancer Viability of Rucaparib for Recurring Ovarian Cancer: A Study Mar 28, 2023
Gynecologic Cancer,Ovarian Cancer 7-Year Follow-Up: Olaparib as First-Line for Advanced Ovarian Cancer Mar 28, 2023
Gynecologic Cancer,Ovarian Cancer Efficacy of First-Line Rucaparib Maintenance for Ovarian Cancer by Disease Risk Subgroups Mar 28, 2023
Gynecologic Cancer,Ovarian Cancer BOOST Phase III Trial: Optimal Duration of Bevacizumab for Ovarian Cancer Mar 27, 2023
Gynecologic Cancer,Ovarian Cancer VELIA Trial: Veliparib as Maintenance Therapy for Frontline Ovarian Cancer Mar 27, 2023
Gynecologic Cancer,Ovarian Cancer Efficacy and Safety of Olaparib by Age in Ovarian Cancer Mar 27, 2023
Gynecologic Cancer,Ovarian Cancer Efficacy of Atezolizumab with Chemo and Bevacizumab in IMagyn050 Trial Mar 27, 2023
